Serial Number
97068213
Owner
Sensyne Health Group LimitedAttorney
Robert B.G. Horowitz, Esq.Filing Date
Oct 11, 2021
SYNE-CHF Trademark
Serial Number: 97068213 • Registration: 6916219
Trademark Classes
Owner Contact Info
Schrödinger Building
Oxford, Oxfordshire OX44GE , GB
Entity Type: 99
Legal Representation
Trademark Details
Filing Date
October 11, 2021
Registration Date
December 6, 2022
Published for Opposition
September 20, 2022
Goods & Services
Recorded and downloadable computer software for use by the healthcare and life sciences business sectors for analyzing patient and clinical trial data in order to support pharmaceutical research and development and to improve direct patient care by providing predictive models to aid physicians in stratifying patients and making appropriate medical interventions for their treatment through the use of algorithms
Designing and developing computer software containing algorithms for use by the healthcare and life sciences business sectors for the purpose of analyzing patient and clinical trial data in order to support pharmaceutical research and development and to improve direct patient care by providing predictive models to aid physicians in stratifying patients and making appropriate medical interventions for their treatment; Software as a Service (SAAS) services in the form of computer software for use by the healthcare and life sciences business sectors for the purpose of analyzing patient and clinical trial data in order to support pharmaceutical research and development and to improve direct patient care by providing predictive models to aid physicians in stratifying patients and making appropriate medical interventions for their treatment through the use of algorithms; Algorithms as a service (AAAS), namely, on-line, non-downloadable software containing algorithms from a cloud-based platform for the design of computer software and computer programming for third-parties in the healthcare and life sciences business sectors for the purpose of analyzing patient and clinical trial data to support pharmaceutical research and development and to improve direct patient care by providing predictive models to aid physicians in stratifying patients and making appropriate medical interventions for their treatment